Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 850 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: Bipolar Disorder, Psychotic Disorders
Interventions: Olanzapine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 2
States / cities: Belmont, Massachusetts • Medford, Massachusetts

Conditions: Schizophrenia
Interventions: bitopertin [RO4917838], olanzapine, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more

Conditions: Healthy
Interventions: Olanzapine, Placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
Interventions: olanzapine and melatonin; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2024
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Sedation, Endoscopy
Interventions: Diphenhydramine, Midazolam; Drug
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Narcolepsy Type 1 (NT1)
Interventions: VX-433, Placebo, Midazolam, Bupropion; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: LY3537982, Digoxin, Rosuvastatin, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Treatment-resistant Depression
Interventions: ketamine, midazolam; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Negative Symptoms in Schizophrenia
Interventions: Roluperidone 64 mg, Olanzapine 10 MG; Drug
Lead sponsor: Minerva Neurosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Garden Grove, California • Gaithersburg, Maryland • Marlton, New Jersey

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Midazolam, Healthy Volunteers
Interventions: Isavuconazole, Midazolam; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Respiratory Insufficiency, Respiratory Distress Syndrome, Newborn, Lung Diseases
Interventions: Team approach to sedation management, Usual approach to sedation management; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 2 Weeks to 18 Years
Enrollment: 2,449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Oakland, California + 26 more

Conditions: Healthy Male Volunteer
Interventions: JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cypress, California

Conditions: Minor Surgical Procedures With Monitored Anesthesia Care, Driving Performance After Minor Ambulatory Surgery
Interventions: Midazolam, Sufentanil, Propofol; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Paravertebral Block, Propofol, Fentanyl, Ropivacaine, Midazolam; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain, IUD
Interventions: Lorazepam 1 mg, Ibuprofen 800 mg; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Agitation
Interventions: Quetiapine, Haloperidol, Lorazepam, Cogentin; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Transgender Persons
Interventions: Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anxiety Disorders
Interventions: Cognitive behavioral therapy for anxiety plus benzodiazepine taper, Health education control plus benzodiazepine taper; Combination Product
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Burbank, California • Los Angeles, California • Santa Monica, California

Conditions: Healthy
Interventions: Cenobamate, midazolam, Warfarin Pill, Omeprazole Pill, Bupropion Pill; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions: Olanzapine, Amantadine, Olanzapine and placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Olanzapine, Metformin, Simvastatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Butner, North Carolina • Durham, North Carolina

Conditions: Anesthesia
Interventions: Dexmedetomidine, Midazolam, Ketamine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 30 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anxiety, Peripheral Nerve Block
Interventions: music, Midazolam; Other · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Metabolic Effects of Olanzapine in Healthy Males

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

Randomized Trial of Diphenhydramine Versus Continued Midazolam in "Difficult-to-sedate" Patients Undergoing Colonoscopy

A Phase 1, First-in-human Study of VX-433

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

Drug Interaction Study of Isavuconazole and Midazolam

Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

Safety of Driving After Minor Surgery With Monitored Anesthesia Care

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

Effect of Testosterone Treatment on Drug Metabolism and Transport

Benzodiazepine Taper With Cognitive Behavioral Therapy in Patients Using Prescription Opioids

Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

Cardio Risk of Acute Schizophrenia Olanzapine Duke

Dexmedetomidine Sedation With Third Molar Surgery

PET Imaging of Peripheral Benzodiazepine Receptors

Music vs Midazolam During Preop Nerve Block Placement